Modality
Cell Therapy
MOA
CAR-T CD19
Target
PRMT5
Pathway
Sphingolipid
Pancreatic CaDMDNB
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
~Nov 2020
→ ~Feb 2022
Phase 2
~May 2022
→ ~Aug 2023
Phase 3
Nov 2023
→ Feb 2028
Phase 3Current
NCT05723326
2,848 pts·DMD
2023-11→2028-02·Active
2,848 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-281.9y awayPh3 Readout· DMD
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P3
Active
Catalysts
Ph3 Readout
2028-02-28 · 1.9y away
DMD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05723326 | Phase 3 | DMD | Active | 2848 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 |